118th Congress Health
S. 1217: Ending the Prescription Drug Kickback Act of 2023
Introduced
- Introduced (completed)
- Passed Senate (not reached)
- Passed House (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill generally prohibits prescription drug manufacturers from providing rebates to pharmacy benefit managers (PBMs) or private health insurance plans.
Specifically, the bill eliminates the safe harbor for rebates, or other payments, provided to PBMs that are intended to influence the applicable cost-sharing tier of the drug (e.g., placing the drug in a more favorable formulary tier).
The bill further prohibits health insurance plans from receiving such rebates with respect to a prescription drug covered by the plan. Plans also must ensure PBMs do not receive any such rebates.
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Who scored on this bill
No member has earned points from it yet.
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
Other bills by Joshua Hawley
- S. 5163: No Bonuses for Bad Service Act
- S. 3062: GUARD Act
- S. 2169: Rural Hospital Cybersecurity Enhancement Act
- S. 3490: National Historical Park and National Historic Landmark Establishment and Boundary Adjustments Act of 2025
- S. 1498: Halting Ownership and Non-Ethical Stock Transactions (HONEST) Act
- S. 1829: STOP CSAM Act of 2025
History
- Introduced in the Senate by Joshua Hawley.
Show the full action history (2 actions)
- Introduced in Senate
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.